ZYVERSA THERAPEUTICS INC (ZVSA) Stock Price, Forecast & Analysis
USA - NASDAQ:ZVSA - US98987D3008 - Common Stock
ZVSA Key Statistics, Chart & Performance
The current stock price of ZVSA is 0.3113 USD. In the past month the price decreased by -50.74%. In the past year, price decreased by -92.04%.
ZVSA Latest News, Press Relases and Analysis
ZVSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.58 | 410.35B | ||
| AMGN | AMGEN INC | 15.36 | 180.89B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.44 | 73.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.14 | 59.51B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.54B | ||
| BIIB | BIOGEN INC | 9.84 | 24.15B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.52 | 20.91B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.49 | 14.30B |
Related stock screener links
About ZVSA
Company Profile
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida and currently employs 7 full-time employees. The company went IPO on 2021-12-21. The firm is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Company Info
ZYVERSA THERAPEUTICS INC
2200 N. Commerce Parkway, Suite 208
Weston FLORIDA US
Employees: 7
Phone: 17542311688
ZYVERSA THERAPEUTICS INC / ZVSA FAQ
Can you describe the business of ZYVERSA THERAPEUTICS INC?
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida and currently employs 7 full-time employees. The company went IPO on 2021-12-21. The firm is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
What is the stock price of ZYVERSA THERAPEUTICS INC today?
The current stock price of ZVSA is 0.3113 USD. The price decreased by -43.3% in the last trading session.
Does ZVSA stock pay dividends?
ZVSA does not pay a dividend.
How is the ChartMill rating for ZYVERSA THERAPEUTICS INC?
ZVSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is ZYVERSA THERAPEUTICS INC (ZVSA) stock traded?
ZVSA stock is listed on the Nasdaq exchange.
Who owns ZYVERSA THERAPEUTICS INC?
You can find the ownership structure of ZYVERSA THERAPEUTICS INC (ZVSA) on the Ownership tab.
Can you provide the short interest for ZVSA stock?
The outstanding short interest for ZYVERSA THERAPEUTICS INC (ZVSA) is 6.74% of its float.
ZVSA Technical Analysis
ZVSA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ZVSA. ZVSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ZVSA Financial Highlights
Over the last trailing twelve months ZVSA reported a non-GAAP Earnings per Share(EPS) of -7.18. The EPS increased by 99.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.14% | ||
| ROE | -108.77% | ||
| Debt/Equity | 0 |
ZVSA Forecast & Estimates
8 analysts have analysed ZVSA and the average price target is 122.4 USD. This implies a price increase of 39218.98% is expected in the next year compared to the current price of 0.3113.